HR Execs on the Move

Pharmaceutical Product Development

www.ppdi.com

 
The Pharmaceutical Product Development, LLC is a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.ppdi.com
  • 929, North Front Street
    Wilmington, NC USA 28401
  • Phone: 910.251.0081

Executives

Name Title Contact Details
Martina KOVAC
VP, Global Product Development-Vaccines | Clinical Research at PPD, part of Thermo Fisher Scientific Profile
Jai Balkissoon
Vice President, Immuno-Oncology,Global Product Development Profile
Sudhakar Sridharan
Executive Medical Director, Global Product Development, Rheumatology & Immunology Profile
Louis Griffel
Executive Medical Director - Global Product Development Profile
Binh Nguyen
VP Global Product Development Profile

Similar Companies

Ceribell

Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.

Pro Med Molded Products Inc

Pro Med Molded Products Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

CPS Instruments

CPS Instruments is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meissa Vaccines

Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens.

jCyte

jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.